Aparna Yellapa1, Pincas Bitterman2, Sameer Sharma3, Alfred S Guirguis4, Janice M Bahr5, Sanjib Basu6, Jacques S Abramowicz7, Animesh Barua8. 1. Department of Pharmacology, Rush University Medical Center, Chicago, IL. 2. Department of Pathology, Rush University Medical Center, Chicago, IL. 3. Department of Pharmacology, Rush University Medical Center, Chicago, IL; Department of Obstetrics and Gynecology, Rush University Medical Center, Chicago, IL. 4. Department of Obstetrics and Gynecology, Rush University Medical Center, Chicago, IL. 5. Department of Animal Sciences, University of Illinois at Urbana-Champaign, Urbana, IL. 6. Department of Preventive Medicine (Biostatistics), Rush University Medical Center, Chicago, IL. 7. Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI. 8. Department of Pharmacology, Rush University Medical Center, Chicago, IL; Department of Pathology, Rush University Medical Center, Chicago, IL; Department of Obstetrics and Gynecology, Rush University Medical Center, Chicago, IL. Electronic address: Animesh_Barua@rush.edu.
Abstract
OBJECTIVE: Long-term unresolved inflammation has been suggested as a risk factor for the development of various malignancies. The goal of this study was to examine whether the expression of interleukin (IL)-16, a proinflammatory cytokine, changes in association with ovarian cancer (OVCA) development. STUDY DESIGN: In an exploratory study, changes in IL-16 expression in association with OVCA development and progression were determined using ovarian tissues and serum samples from healthy subjects (n = 10) and patients with benign (n = 10) and malignant ovarian tumors at early (n = 8) and late (n = 20) stages. In the prospective study, laying hens, a preclinical model of spontaneous OVCA, were monitored (n = 200) for 45 weeks with serum samples collected at 15-week interval. Changes in serum levels of IL-16 relative to OVCA development were examined. RESULTS: The frequency of IL-16-expressing cells increased significantly in patients with OVCA (P < .001) compared to healthy subjects and patients with benign ovarian tumors. The concentration of serum IL-16 was higher in patients with benign tumors (P < .05) than in healthy subjects and increased further in patients with early-stage (P < .05) and late-stage (P < .03) OVCA. Increase in tissue expression and serum levels of IL-16 in patients with early and late stages of OVCA were positively correlated with the increase in ovarian tumor-associated microvessels. Prospective monitoring showed that serum levels of IL-16 increase significantly (P < .002) even before ovarian tumors become grossly detectable in hens. CONCLUSION: This study showed that tissue expression and serum levels of IL-16 increase in association with malignant ovarian tumor development and progression.
OBJECTIVE: Long-term unresolved inflammation has been suggested as a risk factor for the development of various malignancies. The goal of this study was to examine whether the expression of interleukin (IL)-16, a proinflammatory cytokine, changes in association with ovarian cancer (OVCA) development. STUDY DESIGN: In an exploratory study, changes in IL-16 expression in association with OVCA development and progression were determined using ovarian tissues and serum samples from healthy subjects (n = 10) and patients with benign (n = 10) and malignant ovarian tumors at early (n = 8) and late (n = 20) stages. In the prospective study, laying hens, a preclinical model of spontaneous OVCA, were monitored (n = 200) for 45 weeks with serum samples collected at 15-week interval. Changes in serum levels of IL-16 relative to OVCA development were examined. RESULTS: The frequency of IL-16-expressing cells increased significantly in patients with OVCA (P < .001) compared to healthy subjects and patients with benign ovarian tumors. The concentration of serum IL-16 was higher in patients with benign tumors (P < .05) than in healthy subjects and increased further in patients with early-stage (P < .05) and late-stage (P < .03) OVCA. Increase in tissue expression and serum levels of IL-16 in patients with early and late stages of OVCA were positively correlated with the increase in ovarian tumor-associated microvessels. Prospective monitoring showed that serum levels of IL-16 increase significantly (P < .002) even before ovarian tumors become grossly detectable in hens. CONCLUSION: This study showed that tissue expression and serum levels of IL-16 increase in association with malignant ovarian tumor development and progression.
Authors: Donovan Watza; Christine M Lusk; Gregory Dyson; Kristen S Purrington; Kang Chen; Angela S Wenzlaff; Valerie Ratliff; Christine Neslund-Dudas; Gerold Bepler; Ann G Schwartz Journal: Carcinogenesis Date: 2018-12-31 Impact factor: 4.944
Authors: Kamisha T Woolery; Mai Mohamed; Rebecca J Linger; Kimberly P Dobrinski; Jesse Roman; Patricia A Kruk Journal: Biomed Res Int Date: 2015-08-19 Impact factor: 3.411
Authors: Animesh Barua; Aparna Yellapa; Janice M Bahr; Malavika K Adur; Chet W Utterback; Pincas Bitterman; Sanjib Basu; Sameer Sharma; Jacques S Abramowicz Journal: Biomed Res Int Date: 2015-06-16 Impact factor: 3.411
Authors: L Tang; H Shen; X Li; Z Li; Z Liu; J Xu; S Ma; X Zhao; X Bai; M Li; Q Wang; J Ji Journal: Cell Death Dis Date: 2016-03-10 Impact factor: 8.469
Authors: Oliver M T Pearce; Robin M Delaine-Smith; Eleni Maniati; Sam Nichols; Jun Wang; Steffen Böhm; Vinothini Rajeeve; Dayem Ullah; Probir Chakravarty; Roanne R Jones; Anne Montfort; Tom Dowe; John Gribben; J Louise Jones; Hemant M Kocher; Jonathan S Serody; Benjamin G Vincent; John Connelly; James D Brenton; Claude Chelala; Pedro R Cutillas; Michelle Lockley; Conrad Bessant; Martin M Knight; Frances R Balkwill Journal: Cancer Discov Date: 2017-12-01 Impact factor: 39.397
Authors: Katharina Auer; Anna Bachmayr-Heyda; Nyamdelger Sukhbaatar; Stefanie Aust; Klaus G Schmetterer; Samuel M Meier; Christopher Gerner; Christoph Grimm; Reinhard Horvat; Dietmar Pils Journal: Oncotarget Date: 2016-09-20